Skip to main content

8 Result(s)

within M Ruthardt Remove this filter

and

  1. No Access

    Chapter

    Role of Lipoxygenases in Pathogenesis of Cancer

    Increasing evidence in literature implicates lipoxygenases as players in the growth of several solid tumor types, including pancreatic, colorectal, prostate and breast cancer. Recently, a role of 5-lipoxygenas...

    J. Roos, B. Kühn, J. Fettel, I. V. Maucher, M. Ruthardt… in Lipoxygenases in Inflammation (2016)

  2. No Access

    Article

    PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

    Targeting BCR/ABL with tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias. Resistance attributable to either kinase mutations in BCR/ABL...

    A A Mian, A Rafiei, I Haberbosch, A Zeifman, I Titov, V Stroylov, A Metodieva… in Leukemia (2015)

  3. No Access

    Article

    The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation

    The t(6;9)-positive acute myeloid leukemia (AML) is classified as a separate clinical entity because of its early onset and poor prognosis. The hallmark of t(6;9) AML is the expression of the DEK/CAN fusion pr...

    C Oancea, B Rüster, R Henschler, E Puccetti, M Ruthardt in Leukemia (2010)

  4. No Access

    Article

    Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL

    The t(9;22) translocation leads to the formation of the chimeric bcr/abl fusion gene, which encodes the BCR/ABL fusion protein. In contrast to its physiological counterpart c-ABL, the BCR/ABL kinase is constituti...

    A A Mian, C Oancea, Z Zhao, O G Ottmann, M Ruthardt in Leukemia (2009)

  5. No Access

    Article

    The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL

    In Philadelphia chromosome-positive (Ph+) leukemia BCR/ABL induces the leukemic phenotype. Targeted inhibition of BCR/ABL by kinase inhibitors leads to complete remission. However, patients with advanced Ph+ l...

    A A Mian, M Schüll, Z Zhao, C Oancea, A Hundertmark, T Beissert, O G Ottmann… in Leukemia (2009)

  6. No Access

    Article

    Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

    The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk myelodysplastic syndrome (MDS) to the less favorable forms of high-risk MDS, as well as those enabling transform...

    S Boehrer, L Adès, N Tajeddine, W K Hofmann, S Kriener, G Bug, O G Ottmann… in Oncogene (2009)

  7. No Access

    Article

    Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell

    Acute promyelocytic leukemia (APL) is distinguished from other acute myeloid leukemias (AMLs) by cytogenetic, clinical, as well as biological characteristics. The hallmark of APL is the t(15;17), which leads t...

    E Puccetti, M Ruthardt in Leukemia (2004)

  8. No Access

    Chapter and Conference Paper

    Transcriptional Repression of C/EBPα by Histone Deacetylases in Acute Myeloid Leukemia

    In acute myeloid leukemia (AML), fusion proteins such as AMLl-ETO recruit co-repressors and histone deacetylases (HDACs) to their target genes. We compared gene expression in fresh AML blasts with and without ...

    B. Steffen, M. Ruthardt, K. Becker, S. Klümpen, M. Möller… in Acute Leukemias IX (2003)